CHMP smiles on BMS kidney transplant drug
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb won the backing of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for marketing authorization of Nulojix (belatacept) in combination with corticosteroids and a mycophenolic acid for prophylaxis of graft rejection in adults receiving a renal transplant.